1、Molecular Diagnosis of GI Cancer胃肠道肿瘤分子诊断进展Summary,including clinically deployable markers and potential subtype-guided therapies for CRC Part 1Serum levels of TFF3 were significantly elevated in both gastric and colorectal cancer patientsUrine levels of TFF3 were significantly elevated in both gast
2、ric and colorectal cancer patientsSerum TFF3 levels as a prognostic marker for gastric cancerHigher serum TFF3 level was significantly correlated With the clinical stage(I-III vs IV)and distant metastasis Serum levels as a prognostic marker for colorectal cancerHigher serum TFF3 level was significan
3、tly correlated with the clinical stage(I-III v s I V)a n d d i s t a n t metastasis.Older patients(age 60 y)were higher than the levels of;different numbers of lymphatic metastases Serum TFF3 levels as predictors of responses to chemotherapy in gastric and colorectal cancer PR patientsGastric cancer
4、Colon cancer Healthy individualsng/mlSerum level of JTB*P0.0001P60 501.8180.102Lesions 0.764 Colon571.8350.124 Rectum471.9040.121Differentiation 0.057 Well-moderately831.7260.342 Poor 212.0340.524TNM staging(I-II vs III-IV)0.017 I151.5690.126 II351.6050.134 III262.0010.268 IV282.2780.274M i n d i n
5、h a d 7 6.1 5%sensitivity and 81.31%specificity in separating colorectal cancer patients from the normal controls.86.78%sensitivity and 81.25%specificity in separating stage I-II patients and 51.85%sensitivity and 80.21%specificity in separating stage III-IV patients from the healthy controls.ROC cu
6、rve analysisMindin was significantly increased in the PR group after chemotherapy,and its increase was identified as a predictor for chemotherapy response in the PR groupTable 3.Patients with advanced colorectal cancer received chemotherapyPatients IDGenderAgeMindin(ng/mL)CEA(ng/mL)CA199(ng/mL)CA125
7、(ng/mL)TNMEfficacy-0Male541.2834.620.410.5TXN3M1PR-1Male5411.1283.8188.1TXN3M1PR-2Male5410.1874188.1TXN3M1PR-0Male583.2611.26.89.2T4N2M0PD-1Male583.04516.58.7T4N2M0PD-2Male583.0541.37.58.9T4N2M0PD-0Female463.6161.913.913.1T2N0M1PR-1Female463.7262.215.814.9T2N0M1PR-2Female463.5271.81315.9T2N0M1PR-0Ma
8、le680.5311.330.274.2T4aN3M1SD-1Male680.9190.98.824T4aN3M1SD-2Male685.0271.35.926.1T4aN3M1SD-0Female452.35315.9135T3N2M1PR-1Female459.0771.26.560.6T3N2M1PR-2Female4510.0251.65.830.1T3N2M1PR-0Male666.87124.9167T4aN2aM1SD-1Male667.5072.26.365.6T4aN2aM1SD-2Male667.1372.67.840.2T4aN2aM1SD-0Male592.53946.
9、221.811.4T4aN1M1PR-1Male592.491117.5297.216.4T4aN1M1PR-2Male591.83123.544.415.6T4aN1M1PR-0Male621.96210.80.6111.1TXN1M1PR-1Male621.7884.80.642.1TXN1M1PR-2Male621.7066.71.338.5TXN1M1PR-0Male523.11416.7350.86.3T4N0M1SD-1Male523.22312.2270.96.9T4N0M1SD-2Male523.0188.22345.9T4N0M1SD-0Male732.114410.47.5
10、T3N0M1SD-1Male732.681310.86.7T3N0M1SD-2Male734.0493.310.58.3T3N0M1SD-0Female561.464710.420.7866.1T3N2M1SD-1Female5610.9536.65.229.5T3N2M1SD-2Female5610.5123.04.317.6T3N2M1SD-0Male521.78312.712.87.1TXN0M1SD-1Male521.55.71814.1TXN0M1SD-2Male523.01147.86.5TXN0M1SD-0Female451.224116.8549.211T4N2M1PR-1Fe
11、male450.67295.9720.414.3T4N2M1PR-2Female4510.63525.9220.414.3T4N2M1PREGR1MindinExpressionEGR1cgcccccgccancerMindin promoterResults Future plan分子机制信号通路MindinWestern blotWestern blot血清学检测RT-PCR报告基因EGR1组织中表达CH-IPWestern blotRT-PCR组织中表达Combination of TFF3,JTB and Mindin for Early Diagnosis of GI Cancer!Our Goal28我力有限，靠你众力搏程；我力有限，靠你定向领航；遥遥苦辛路，浓浓同路情；为了那一天，启程
